Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac          biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral          valve disease

Mizuki OGAWA; Yasutomo HORI; Nobuyuki KANNO; Naoki IWASA; Takeshi TOYOFUKU; Noriko ISAYAMA; Akane YOSHIKAWA; Ryota AKABANE; Atsushi SAKATANI; Hirosumi MIYAKAWA; Huai-Hsun HSU; Yuichi MIYAGAWA; Naoyuki TAKEMURA

doi:10.1292/jvms.20-0629

Internal Medicine

Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease

Mizuki OGAWA, Yasutomo HORI, Nobuyuki KANNO, Naoki IWASA, Takeshi TOYOFUKU, Noriko ISAYAMA, Akane YOSHIKAWA, Ryota AKABANE, Atsushi SAKATANI, Hirosumi MIYAKAWA, Huai-Hsun HSU, Yuichi MIYAGAWA, Naoyuki TAKEMURA

Author information

Mizuki OGAWA
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Yasutomo HORI
Otsuka-Ekimae Animal Hospital, 1-20-7 Kitaotsuka, Toshima-ku, Tokyo 170-0004, Japan
Nobuyuki KANNO
Saitama Animal Medical Centre, 2-2-15 Sayamadai Iruma-shi, Saitama 358-0033, Japan
Naoki IWASA
Hashima Animal Hospital, 2-17 Asahira, Fukujyu-cho, Hashima, Gifu 501-6255, Japan
Takeshi TOYOFUKU
Nishigahara Rose Animal Hospital, 1-25-32 Nishigahara, Kita-ku, Tokyo 114-0024, Japan
Noriko ISAYAMA
Uenonomori Animal Clinic, 1-5-11 Yanaka Taito-ku, Tokyo 114-0024, Japan
Akane YOSHIKAWA
Meguro Animal Medical Center, 3-9-3-104 Meguro, Meguro-ku, Tokyo 153-0063, Japan
Ryota AKABANE
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Atsushi SAKATANI
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Hirosumi MIYAKAWA
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Huai-Hsun HSU
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Yuichi MIYAGAWA
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan
Naoyuki TAKEMURA
Laboratory of Veterinary Internal Medicine II, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo 180-8602, Japan

Keywords: cardiac biomarker, myxomatous mitral valve disease, N-terminal pro-atrial natriuretic peptide, N-terminal pro-brain natriuretic peptide

JOURNAL OPEN ACCESS

2021 Volume 83 Issue 4 Pages 705-715

DOI https://doi.org/10.1292/jvms.20-0629

Browse “Advance online publication” version

Details

Abstract

Plasma N-terminal pro-atrial natriuretic peptide (NT-proANP) concentration increases with progression of myxomatous mitral valve disease (MMVD) in dogs. This multicentre, prospective study compared plasma NT-proANP, N-terminal pro-brain natriuretic peptide (NT-proBNP), ANP, and cardiac troponin I (cTnI) concentrations in dogs with MMVD for their characteristics and discriminatory ability to detect cardiac dilatation and congestive heart failure (CHF). Thirty-six healthy dogs and 69 dogs with MMVD were included. Clinical variables were obtained via physical examination, thoracic radiography, and echocardiography. The discriminatory ability of each cardiac biomarker (CB) to determine the presence or absence of cardiac dilatation (event 1) and CHF (event 2) was evaluated using the receiver operating characteristic curves. Plasma NT-proANP, NT-proBNP, and ANP concentrations showed a significant association with the left atrium/aorta ratio (P<0.01). The area under the curve of plasma NT-proANP and NT-proBNP concentrations were 0.72 and 0.75, respectively in event1 and 0.72 and 0.76, respectively in event2. Plasma NT-proANP and NT-proBNP concentrations showed sensitivity 80.0 and 80.0%; specificity 67.6 and 64.7% in event1 (cutoff value; 8,497.81 pg/ml and 1,453.00 pmol/l, respectively) and sensitivity 85.7 and 81.0%; specificity 60.4 and 64.6% in event2 (cutoff value; 8,684.33 pg/ml and 1,772.00 pmol/l, respectively). In dogs with MMVD, plasma NT-proANP, NT-proBNP, and ANP concentrations increase with left atrial enlargement. Particularly, plasma NT-proANP and NT-proBNP concentrations appeared to be equally useful in the discriminatory ability to detect cardiac dilatation and CHF.

Corresponding author

Register with J-STAGE for free!